Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis has started the construction of a new greenfield pharmaceutical manufacturing plant in St. Petersburg, as part of a $500m five-year investment into Russian healthcare infrastructure announced in December 2010.
Subscribe to our email newsletter
The facility will be constructed in the Novoorlovskaya Special Economic Zone (SEZ), located to the north of the St. Petersburg city center.
Once completed and approved for commercial production, which is expected in 2014, the facility will produce approximately 1.5 billion units of both innovative pharmaceuticals and generics per year.
Novartis CEO Joseph Jimenez said the plant in St. Petersburg is the latest step in their strategy to bring both innovative pharmaceuticals and low cost, high quality generics closer to patients and customers in Russia.